510(k) vs. De Novo vs. PMA: Choosing the Right FDA Pathway

Every medical device company reaches the same fork in the road: which FDA pathway fits the device in front of them. Choosing wrong doesn’t just cost time — it can mean building an entire evidence package for the wrong evidentiary standard, then rebuilding it under regulatory pressure. This article walks through how the three primary pathways — 510(k), De Novo, and PMA — actually differ in practice, and how sponsors should be thinking about the decision in 2026.

The Core Distinction: Equivalence vs. Novelty vs. Risk

The three pathways aren’t really parallel options — they answer three different regulatory questions.

510(k) asks: is this substantially equivalent to something already on the market? A 510(k) clearance doesn’t require proof that a device is safe and effective in isolation. It requires proof that the device has the same intended use and technological characteristics as a legally marketed predicate device, or that any differences don’t raise new questions of safety or effectiveness. This is why 510(k) remains the dominant pathway for Class II devices — it leverages existing clinical and safety data rather than generating it from scratch.

De Novo asks: is this novel, but still manageable through general and special controls? When a device has no valid predicate but the underlying risk profile is low-to-moderate, De Novo lets a sponsor request a risk-based classification directly, without a preceding 510(k) submission being denied. Critically, a granted De Novo creates a new predicate — meaning the next company with a similar device can file a 510(k) against it. This makes De Novo strategically valuable for first movers in an emerging device category.

PMA asks: is this safe and effective, on its own merits, supported by valid scientific evidence? Premarket Approval is reserved for Class III devices — those that support or sustain human life, are of substantial importance in preventing impairment of health, or present a potential unreasonable risk of illness or injury. PMA is the most resource-intensive pathway by a wide margin, typically requiring clinical trial data, manufacturing information, and a much deeper FDA review.

Decision Criteria: How Sponsors Should Actually Choose

In practice, the decision isn’t made in the abstract — it’s made against a small set of concrete questions:

Does a predicate exist? This is the threshold question. A predicate search isn’t just a legal formality; it shapes the entire regulatory strategy. If a reasonably close predicate exists — even one with some technological differences — a 510(k) with supporting bench, biocompatibility, or performance testing is usually the fastest and least expensive route to market.

If no predicate exists, is the risk profile still low-to-moderate? This is where De Novo becomes relevant. FDA’s De Novo guidance emphasizes that the pathway is appropriate when general controls, or general and special controls, provide a reasonable assurance of safety and effectiveness — even without a predicate. Sponsors sometimes default to assuming novelty automatically means PMA; that assumption is often wrong and expensive.

Does the device carry Class III-level risk, or support/sustain life? If so, PMA is very likely unavoidable, and the sponsor should plan for a clinical evidence strategy — including early engagement with FDA through the Q-Submission program — well before manufacturing scale-up begins.

Is there a combination product angle? Devices that incorporate a drug or biologic component (drug-eluting stents, prefilled injector-drug combinations) trigger a jurisdictional determination through FDA’s Office of Combination Products, which can significantly change both the pathway and the review division involved. Sponsors should request a formal designation request (RFD) early if jurisdiction is ambiguous, rather than assuming device-led review applies.

Timeline and Resource Reality

The pathways differ enormously in review burden, and sponsors consistently underestimate this gap during early planning:

• 510(k): FDA’s stated goal is a 90-day review clock, though total time-to-clearance (including Additional Information cycles) commonly runs longer in practice. Evidence requirements are typically limited to bench testing, biocompatibility, and sometimes limited clinical data.

• De Novo: FDA’s target review timeline is 150 days, but De Novo requests generally require a more substantial evidentiary package than a straightforward 510(k), since there’s no predicate to lean on for comparative claims.

• PMA: FDA’s goal is a 180-day review, but this clock only starts once the application is accepted as complete — and PMA applications routinely involve years of preceding clinical trial work, IDE studies, and manufacturing validation before submission is even possible.

  Where the Breakthrough Devices Program Intersects

Sponsors of higher-risk, more novel technologies increasingly layer the Breakthrough Devices Program on top of whichever pathway applies — 510(k), De Novo, or PMA — rather than choosing between them. As of March 2026, CDRH and CBER had granted 1,284 Breakthrough Device designations since the program's 2016 inception (including devices carried over from the precursor Expedited Access Pathway), with 198 of those devices having gone on to receive marketing authorization. Breakthrough designation doesn't change which pathway applies; it changes the intensity of FDA interaction during development — more frequent Q-Submission meetings, priority review, and in some cases, alternative or streamlined evidence generation approaches negotiated directly with the review division.

A Practical Framework

For teams building out regulatory strategy, a simple sequence works better than treating pathway selection as a single decision point:

• Run a predicate search before anything else — this determines whether 510(k) is even on the table.

• If no predicate exists, assess risk classification honestly against FDA's De Novo criteria before assuming PMA is required.

• If Class III risk is confirmed, begin PMA planning immediately, including early Q-Submission engagement, since clinical evidence generation is the long pole in the timeline.

• Evaluate Breakthrough Device eligibility in parallel — it's a program layered on top of the pathway decision, not a substitute for it.

• Flag combination product characteristics early; jurisdictional ambiguity resolved late in development is one of the most common causes of costly rework.

The pathway decision shapes everything downstream — clinical strategy, quality system scope, submission timeline, and cost. Getting it right at the outset is one of the highest-leverage regulatory decisions a device company makes.

This article reflects FDA guidance and publicly available program data as of 2026 and is intended for general regulatory and educational purposes. It does not constitute regulatory or legal advice for a specific device or submission.